1. Home
  2. HPH vs IVA Comparison

HPH vs IVA Comparison

Compare HPH & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HPH
  • IVA
  • Stock Information
  • Founded
  • HPH 2010
  • IVA 2011
  • Country
  • HPH China
  • IVA France
  • Employees
  • HPH N/A
  • IVA N/A
  • Industry
  • HPH
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HPH
  • IVA Health Care
  • Exchange
  • HPH NYSE
  • IVA Nasdaq
  • Market Cap
  • HPH 137.1M
  • IVA 117.3M
  • IPO Year
  • HPH 2019
  • IVA 2020
  • Fundamental
  • Price
  • HPH $0.27
  • IVA $2.16
  • Analyst Decision
  • HPH
  • IVA Strong Buy
  • Analyst Count
  • HPH 0
  • IVA 4
  • Target Price
  • HPH N/A
  • IVA $13.25
  • AVG Volume (30 Days)
  • HPH 142.5K
  • IVA 7.3K
  • Earning Date
  • HPH 01-01-0001
  • IVA 09-25-2024
  • Dividend Yield
  • HPH N/A
  • IVA N/A
  • EPS Growth
  • HPH N/A
  • IVA N/A
  • EPS
  • HPH N/A
  • IVA N/A
  • Revenue
  • HPH $286,996,105.00
  • IVA $20,652,523.00
  • Revenue This Year
  • HPH N/A
  • IVA N/A
  • Revenue Next Year
  • HPH N/A
  • IVA $361.78
  • P/E Ratio
  • HPH N/A
  • IVA N/A
  • Revenue Growth
  • HPH 1722.42
  • IVA N/A
  • 52 Week Low
  • HPH $0.23
  • IVA $1.53
  • 52 Week High
  • HPH $10.06
  • IVA $4.50
  • Technical
  • Relative Strength Index (RSI)
  • HPH 39.75
  • IVA 38.30
  • Support Level
  • HPH $0.23
  • IVA $2.11
  • Resistance Level
  • HPH $0.29
  • IVA $2.24
  • Average True Range (ATR)
  • HPH 0.05
  • IVA 0.07
  • MACD
  • HPH -0.00
  • IVA 0.01
  • Stochastic Oscillator
  • HPH 15.83
  • IVA 22.07

About HPH HIGHEST PERFORMANCE HLDGS INC

Highest Performances Holdings Inc is a financial technology service group based on family financial asset allocation. It focuses on providing personalized wealth management services for emerging middle-class and affluent families, comprehensive support services for financial planners, and diversified financial services for institutional clients.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: